111 Capital Makes New $517,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• 111 Capital has made a new investment of approximately $517,000 in Regeneron Pharmaceuticals by acquiring 985 shares during the second quarter.
• Several institutional investors have significantly increased their stakes in Regeneron, with E Fund Management Hong Kong increasing its shares by 344.4% in the first quarter.
• Analysts have a positive outlook on Regeneron Pharmaceuticals, with a consensus rating of "Moderate Buy" and an average price target of $817.67 per share.

111 Capital bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 985 shares of the biopharmaceutical company's stock, valued at approximately $517,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. Activest Wealth Management increased its stake in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Finally, Colonial Trust Advisors acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on REGN shares. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Jefferies Financial Group lifted their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. Finally, Raymond James Financial upgraded Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $600.00 on Monday. The business's 50 day simple moving average is $572.12 and its 200 day simple moving average is $566.55. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,024.36. The firm has a market cap of $63.59 billion, a PE ratio of 15.12, a P/E/G ratio of 1.92 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the firm earned $11.56 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.